Madrigal Pharmaceuticals beat Q1 sales estimates with Rezdiffra, and catalysts like EU approval and pipeline plans add upside ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

Shares of Akero Therapeutics (NASDAQ:AKRO) climbed on Tuesday after StreetInsider reported that the San Francisco, California ...

Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage.

Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for ...

To know more about liver fibrosis treatment options, visit @ New Treatment for Liver Fibrosis The approval of REZDIFFRA (resmetirom) in March 2024 represents a major advancement in the treatment ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Though the history of MASH research is marked by many clinical trial failures and regulatory setbacks, the FDA last year approved the first MASH treatment, a once-daily pill called Rezdiffra from ...